New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
10:00 EDTEEP, WSH, NFX, LLY, FCX, SNBC, MON, AYI, SPLK, OPEN, INTCOn The Fly: Analyst Upgrade Summary
Acuity Brands (AYI) upgraded to Buy from Hold at Canaccord... Eli Lilly (LLY) upgraded to Outperform from Market Perform at Cowen... Intel (INTC) upgraded to Overweight from Neutral at Piper Jaffray... Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan... Newfield Exploration (NFX) upgraded to Buy from Neutral at UBS... OpenTable (OPEN) upgraded to Buy from Neutral at Citigroup... Sun Bancorp (SNBC) upgraded to Neutral from Underperform at Sterne Agee... Willis Group (WSH) upgraded to Buy from Neutral at Nomura... Splunk (SPLK) upgraded to Outperform from Underperform at CLSA... Freeport McMoRan (FCX) upgraded to Outperform from Neutral at Macquarie... Enbridge Energy (EEP) upgraded at Credit Suisse.
News For AYI;LLY;INTC;MON;NFX;OPEN;SNBC;WSH;SPLK;FCX;EEP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 22, 2015
15:23 EDTFCXFreeport operations at Grasberg resume as blockade ends, Reuters says
Freeport McMoRan has reopened an access road at its Grasberg mine in Indonesia that was blocked by a demonstration last week and says normal operations were being resumed at the mine, says Reuters. Reference Link
14:27 EDTMONWHO says herbicide marketed by Monsanto likely carcinogenic, WSJ says
A World Health Organization agency said Friday that Glyphosate, a herbicide marketed by Monsanto under the Roundup brand and other companies, has the potential to cause cancer in humans, says the Wall Street Journal. Monsanto contested the findings saying that glyphosate is safe if used as recommended by its label and that decades of extensive study have proven its safety, added the Wall Street Journal. Reference Link
March 20, 2015
11:33 EDTLLYFly Review: Analysts correctly predict jump in Biogen shares
The shares of Biogen (BIIB) are rallying after the company reported results for a Phase 1b study of its Alzheimer's drug, BIIB-037. On March 18, as reported on that day by The Fly, RBC Capital predicted that the stock would rise after the results were published. A number of other firms were also upbeat on the stock ahead of the data release. WHAT'S NEW: Earlier this morning Biogen announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. Beta amyloid is a protein that produces plaque in the brain. Scientists suspect that plaques in the brain are a cause of Alzheimer's. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. PRE-EVENT CALLS: RBC Capital analyst Michael Yee predicted earlier this week in a note to investors that Biogen would report strong data for BIIB-037 and the stock should "work higher" after the data is unveiled. Alzheimer's patients taking the high dose of Biogen's BIIB-037 drug should exhibit a stabilization of cognition levels, Yee stated. Conversely, the cognition levels of patients taking the placebo should drop slightly, the analyst predicted. On March 13, in a note summarized by The Fly on that day, JPMorgan recommended buying Biogen shares ahead of the data release. Investors still incorporated a low probability of success for the drug, and the stock could rise further, the firm wrote. On March 19, in a note also published by The Fly, Credit Suisse wrote that Biogen's multiple could rise if the data on BIIB-037 was positive. It raised its price target on the name to $500 from $400. ANALYST REACTION: This morning, Barclays raised Biogen's price target to $500 from $435 following the company's report of "impressive" full results from the Alzheimer's study. Piper Jaffray analyst Joshua Schimmer also raised his price target for Biogen shares to $500 this morning, calling today’s BIIB-037 results "robust and impressive." Schimmer believes the trial showed a "consistent and dramatic" dose effect on both radiographic and clinical disease features and thinks the side effects "pale in comparison" to the drug’s efficacy. OTHERS TO WATCH: Eli Lilly (LLY) and Roche (RHHBY) are also currently developing similar Alzheimer's treatments. PRICE ACTION: In late morning trading, Biogen rose 7% to $464. The stock is up about 9% since Wednesday. Eli Lilly shares are up 1.6% to $75.40 this morning, while Roche rose 2.2% to $35. Reference Link
10:43 EDTFCXStocks with call strike movement; CHK FCX
Chesapeake (CHK) July 16 call option implied volatility increased 2% to 50, Freeport McMoRan (FCX) August 20 call option implied volatility decreased 6% to 47 according to IVolatility.
09:57 EDTLLYLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:01 EDTLLYEli Lilly up 2% to $75.75 in pre-market trading
Subscribe for More Information
08:01 EDTLLYEli Lilly and Innovent Biologics announce strategic alliance
Subscribe for More Information
07:41 EDTLLYAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
07:24 EDTINTCBroadcom chip renews competition with in-house hardware makers, WSJ says
Subscribe for More Information
March 19, 2015
10:46 EDTINTCChinese firms using IBM technology in server chips, WSJ says
Subscribe for More Information
09:02 EDTINTCIntel, Google, TAG Heuer announce Swiss smartwatch collaboration
Subscribe for More Information
08:40 EDTINTCIntel Capital in talks to invest in Indian streaming service, TechCrunch says
Subscribe for More Information
08:08 EDTLLYEli Lilly and Hanmi sign license and collaboration agreement
Subscribe for More Information
06:59 EDTFCXProduction at Freeport McMoRan mine in Indonesia halted, Reuters reports
Subscribe for More Information
March 18, 2015
14:37 EDTMONMonsanto and midwest, southeast wheat farmers reach settlement agreement
Subscribe for More Information
12:48 EDTLLYFly Watch: Biogen predicted to report strong Alzheimer's data this Friday
Subscribe for More Information
11:03 EDTFCXStocks with call strike movement; NE FCX
Noble Corp. (NE) June 16 call option implied volatility increased 2% to 54, Freeport McMoRan (FCX) August 21 call option implied volatility increased 2% to 49 according to IVolatility.
08:59 EDTAYIAcuity Brands price target raised to $172 from $163 at RW Baird
Baird raised its price target to $172 from $163 citing improved market growth, strong cyclical fundamentals, and favorable long-term risk/reward. Baird reiterated its Outperform rating on Acuity Brands shares.
07:46 EDTLLYLilly Roche would have upbeat read through from strong BIIB data, says Bernstein
Bernstein notes that the data for Biogen's (BIIB) Alzheimer's treatment, due to be released on Friday, is widely expected to be positive. The firm thinks that positive data would boost the outlook for similar Alzheimer's drugs being developed by Eli Lilly (LLY) and Roche (RHHBY), since consensus estimates for those drugs are low. The firm keeps Outperform ratings on Eli Lilly and Roche.
07:27 EDTFCXFreeport seeks funding from Blackstone, Apollo, Reuters says
Freeport McMoRan (FCX) has hired Goldman Sachs (GS) and Barclays (BCS) to find private equity firms willing to finance certain of its energy projects and asset developments, reports Reuters, citing people familiar with the matter. Freeport is in talks with Blackstone (BX), Apollo (APO), and Warburg Pincus about a potential partnership. The sources say the firm may be seeking "several billion dollars," though discussions are in "very early" stages. Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use